A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

J Exp Clin Cancer Res · 2022 · PMC9161616 · PMID 35655320

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

A positive trend regarding the activity of FGF401 in groups 1 and 2 was concluded if the observed lower limit of their respective 90% CI was no less than their expected median TTPs of 1.5 months and 2.2 months estimated in the absence of FGF401.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.